Side-effect fears hold back 67.0% of US adults from a recommended statin, and a test of their own heart risk, not a lower price, is what would change their minds
Worry about side effects is the main thing that would stop 67.0% of US adults starting a daily statin their doctor recommends while they feel well (n=200, October 2026), while 62.5% say a test showing their own heart risk is high would most persuade them to start, against 1.0% who name a lower price.
- Who was asked
- US adults, 200 clones, US
- When
- October 2026 (fielded 5 October 2026)
- How
- Predicted responses from Brox clones, each built from a long-form interview with a real person.
- What changed from the obvious question
- The obvious question asks people to list their barriers. We asked for the ONE main barrier and the ONE main persuader separately, and priced the same pill twice, so the gap between what people name and what changes their answer can be seen.
Section 01: What the panel said
- #
67%
67.0% say worry about side effects would most hold them back from starting a statin their doctor recommends while they feel well; 19.5% would rather try diet and exercise first and 2.5% name the monthly cost.
base 200
- #
62.5%
62.5% say a test showing their own heart risk is high would most persuade them to start, against 18.5% for a three-month trial, 11.0% for being told in plain numbers how much the pill lowers risk and 1.0% for a lower cost.
base 200
- #
54%
Willingness to start falls from 70.5% at $10 a month to 54.0% at $45 a month, although only 2.5% name cost as their main barrier.
base 200 · contrast
- #
79.1%
The side-effect worry is a hesitation more than a refusal: 79.1% of those who name it would still probably or definitely start at $10 a month.
base 134 · Clones whose main barrier is worry about side effects · caveat
67.0% say worry about side effects would most hold them back from starting a statin their doctor recommends while they feel well; 19.5% would rather try diet and exercise first and 2.5% name the monthly cost.
02Why do side-effect worries and a personal risk test go together?
Side effects are the barrier people name, but they are not the thing that unlocks a start. Of the 134 clones whose main hesitation was side effects, 80 (59.7%) said a test showing their own heart risk is high would most persuade them, and only 33 (24.6%) chose a three-month trial to see how they feel on the pill.
The reading we find most interesting is that a feeling-fine patient is weighing a known cost (possible side effects) against a benefit they cannot see. Reassurance about safety answers the first half of that sum. A personal result answers the second, and that is the half the panel asks for. This is our reading of the pattern, not a question the panel was asked directly.
The worry is also a hesitation more than a refusal: 106 of those 134 clones (79.1%) still said they would probably or definitely start at $10 a month.
03Does price matter if almost nobody names it?
Only 5 of 200 clones named the monthly cost as their main barrier, and 2 of 200 said a lower cost would most persuade them. Yet when the same pill was priced at $45 a month instead of $10, the share who would probably or definitely start fell from 70.5% to 54.0% (n=200), and the share who would definitely start halved from 25.5% to 12.0%. Of the 141 clones who would start at $10, 33 would not at $45.
The fall is steepest on lower incomes. Among clones with household income under $50,000, willingness to start went from 69.3% to 41.3% (n=75); at $50,000 and above it went from 71.0% to 62.1% (n=124).
04Who would rather try diet and exercise first?
A preference for lifestyle change first is the second barrier at 19.5% (n=200), and it sits mostly in middle age: 19 of 68 clones aged 45 to 64 (27.9%) chose it, against 3 of 48 aged 65 and over. The older group is the most side-effect focused, with 40 of 48 naming side effects.
Several of the diet-first clones describe having done exactly this when a statin was suggested to them, so for this group the barrier is a plan rather than a doubt about risk.
05What could a brand or health team do with this?
- Lead with the patient's own number. A reading, not the panel's words: the conversation that moves a well-feeling patient is one about their personal risk, with side effects addressed second.
- Treat price as a silent barrier. Patients will rarely say cost is the reason, so a copay or savings route belongs in the first conversation, especially for lower-income patients.
- Give the diet-first group a dated plan. A set period of lifestyle change followed by a recheck respects the plan they already hold and keeps the medicine on the table.
Section 06: What they said, and the interview line it rests on
“Without a doubt, it would be worry about side effects. First and foremost, when it comes to taking any medication, side effects are my primary concern. I need to know that a drug is going to help me without hurting me or creating more problems than I started with. Even if my cholesterol is high, if a medicine causes any adverse reactions or doesn't agree with my system, I will stop taking it immediately.”
Predicted from this line in the interview
“I would immediately discontinue using a medication if I feel like it's creating more problems.”
“If I felt completely fine, the thing that would most persuade me would definitely be a test result showing my own heart risk is high. I am sometimes hesitant with prescription medications because I've had bad reactions to medicines in the past, and I don't like doing medical things that aren't really necessary. So to decide to take a daily pill, I would need to see the actual results from my doctor showing that my own risk is high and that I truly need it. Thank you.”
Predicted from this line in the interview
“And the opinions that matter to me are doctors showing me results, seeing real people have the results and not having severe effects”
“I would definitely choose to try diet and exercise first. In fact, that's exactly what I did in real life when my doctor recommended a statin for my elevated cholesterol. Before agreeing to go on any prescription medication, I wanted to see if I could bring my numbers down on my own by watching what I eat, losing weight, and getting more exercise. I really prefer to avoid taking medicine if I can help it, so I put off starting the statin until I had given lifestyle changes a fair shot.”
Predicted from this line in the interview
“Well, yes, I chose not to go on statins for my elevated cholesterol levels because I wanted to see if I could reduce the levels satisfactorily by changing my diet, losing weight, exercising more. So I did put that off.”
Section 07: How much should you trust this?
What we would defend
- Side effects lead as the named barrier by a wide margin, 67.0% against 19.5% for the next option (n=200), and lead in every age group and both genders.
- A personal heart-risk test is the leading persuader overall (62.5%, n=200) and among the side-effect worriers themselves (80 of 134).
- Every clone moved down or stayed put between $10 and $45; none moved up, and the reasoning at $45 cites the $45 figure in 142 of 200 answers and never the $10 one.
What we would not
- The exact size of the price effect: every clone saw both prices one after the other, so the 70.5% to 54.0% fall is a direction, not a forecast of uptake at either price.
- The income split (n=75 under $50,000, n=124 at $50,000 and above) as more than a direction.
- Extending the statin result to every preventive medicine: the study names one medicine and one benefit.
- The persuasion figures as demand: a forced pick has no cost or effort attached, and 24 of 200 barrier answers mention already taking a cholesterol or heart medicine, so for them the scenario is hypothetical.
The main limitation
The scenario is one daily statin for a person who feels well, asked of a general US healthcare panel rather than people who have just been prescribed one, and both prices were shown to the same clones in sequence.
Section 08: How was this run?
| Segment | Clones |
|---|---|
| Aged 18 to 29 | 26 |
| Aged 30 to 44 | 58 |
| Aged 45 to 64 | 68 |
| Aged 65 and over | 48 |
| Women | 105 |
| Men | 95 |
Question wording as fielded
- Your doctor recommends you start a daily cholesterol-lowering pill (a statin) to lower your risk of a heart attack over the next ten years. You feel completely well today. How likely are you to start taking it within the next month? Asked at two prices: the pill costs you $10 a month after insurance; the pill costs you $45 a month after insurance.
- If your doctor recommended a daily cholesterol-lowering pill (a statin) while you felt completely well, which ONE of these would most hold you back from starting it?
- If your doctor recommended a daily cholesterol-lowering pill (a statin) while you felt completely well, which ONE of these would most persuade you to start it?
What was not asked, and why
We did not ask about any named statin or brand, about doctor trust, or about past prescriptions, because the panel cannot be relied on to recall its own prescribing history. Cost was tested as two fully stated monthly prices rather than as an open question.
What changed from the obvious question
The obvious question asks people to list their barriers. We asked for the ONE main barrier and the ONE main persuader separately, and priced the same pill twice, so the gap between what people name and what changes their answer can be seen.
Fielded through Ask Brox on 5 October 2026.
More on Why patients stay on a medicine, and why they stop · Pharma & HCP · Healthcare (US) panel
Ask this of your own customers: humans@brox.ai
Related insights
All in this topic-
Patient adherence breaks at the copay: 48.5% would stop a daily blood pressure pill when it jumps from $15 to $60 a month
48.5% 48.5% would stop the blood pressure pill once its copay rose from $15 to $60 a month, on top of no felt benefit and afternoon tiredness, up from 14.0% with the tiredness alone and 1.5% with no felt benefit alone. (base 200)
Read -
Antidepressant cost: only 35.0% of US adults prescribed one for depression would stay on it at $150 a month, against 82.2% at $50
35% 35.0% would stay on an antidepressant that is helping at $150 a month, against 82.2% at $50 and 97.0% at $10; no clone rates itself more likely to stay on at a higher price. (base 197)
Read -
Seeing it work keeps US adults on a statin they cannot feel: a cholesterol test result wins over 92.2% of those not yet certain, home delivery 27.5%, and a $30 a month rise is the top reason to stop below $50,000 a year
98% A follow-up blood test showing cholesterol down by a third lifts the share of US adults very likely to still be taking a daily statin a year later from 74.5% to 98.0%; automatic home delivery every three months at the same $10 a month lifts it to 80.5%. Every case had no side effects and no change in how the person feels. (base 200)
Read -
Cash to go ahead with a delayed $3,000 treatment: no US adult would for under $1,000, and 97 of 200 would need the full $3,000
0 There is no cheap nudge. Not one person in 200 would proceed for less than $1,000. (base 200)
Read